Integrated Clinical, Tissue, and Biomarker Data Base Core (ICTBD Core)

摘要（共享资源-ICTBD核心） 集成临床和组织生物储存库/生物标志物数据库（ICTBD）核心的总体目标是 加强和升级我们目前的ICTBD核心，该核心与我们的临床资源核心相结合。这将 通过多维度的转化研究方法来实现， 合作伙伴的研究/外展核心、临床网络、社区合作伙伴和学术合作伙伴 通过第一个U 54资助周期（2009-2015）开发。该伙伴关系使用转化研究 根据两个翻译模块（T1-基础/生物医学研究和T2-临床/实施 研究）。在第二个54岁以下儿童周期（2015-2020年），伙伴关系建议利用信通技术促发展核心， 加强现有的T1活动，并促进将第一个U 54周期开发的项目从T1转移到T2。 我们将通过以下方式实现这一目标：1）继续建立网络，以加强生物标本/数据 收集和促进转化研究，2）提供患者同意/参与生物标本， 临床研究协议，3）促进双向交流，教育/培训的平台，以及 在伙伴关系的T1/T2活动和社区癌症外展之间传播信息 核心，4）为T1至T2过渡提供行政支持，如IRB准备、监测和患者 招募，以提高代表性不足的患者参与临床试验，和5）与合作伙伴关系， 我们的社区合作伙伴和社区肿瘤学家继续建立和维持一个全面的 生物标本库，重点关注非裔美国人和拉丁美洲人的乳腺癌、结肠癌和前列腺癌 为了鉴定用于评估癌症发病和进展风险的新标记物， 可能是种族群体所独有的，并减少癌症健康差异。这些活动将双重丰富 通过加强CDU的翻译研究机构能力， UCLA-JCCC资源，并使UCLA-JCCC的机会多样化，以改善代表性不足的人的参与 参与研究。

ABSTRACT (Shared Resources-ICTBD Core) The overall objective of the Integrated Clinical and Tissue Biorepository/Biomarker Data Base (ICTBD) Core is to enhance and upgrade our current ICTBD Core which is integrated with our Clinical Resource Core. This will be accomplished through a multi-dimensional translational research approach which leverages the Partnership's research/outreach Cores, clinical networks, community partners, and academic partners developed through the 1st U54 funding cycle (2009-2015). The Partnership uses Translational Research according to the two translational blocks (T1- Basic/Biomedical Research and T2- Clinical/Implementation Research). During the 2nd U54 Cycle (2015-2020), the Partnership proposes to utilize the ICTBD Core to both enhance existing T1 activities, and facilitate the transfer of projects developed in 1st U54 cycle from T1 to T2. We will accomplish this through the following: 1) continue building networks to enhance biospecimen/data collection and facilitate translational research, 2) provide patient consent/engagement into biospecimen and clinical research protocols, 3) facilitate a platform of bi-directional exchange, education/training, and information dissemination between the Partnership's T1/T2 activities and the Community Cancer Outreach Core, 4) provide administrative support for T1 to T2 transition such as IRB preparation, monitoring, and patient recruitment to enhance underrepresented patient participation in clinical trials, and 5) work in partnership with our community partners and community oncologists to continue to build and sustain a comprehensive biospecimen repository with focus on breast, colon, and prostate cancers from African Americans and Latinos for the purpose of identification of novel markers for assessing risk of cancer incidence and progression that may be unique to ethnic groups and reduce cancer health disparities. These activities will dually enrich both sides of the CDU/UCLA Partnership by bolstering CDU's institutional capacity for translational research with UCLA-JCCC resources, and diversifying access for UCLA-JCCC to improve engagement of underrepresented participants in research.